Amneal Pharmaceuticals Company GmbH and Iconovo AB Execute Development and License Agreement / by TI

Zug, Switzerland, June 14, 2016 – Amneal Pharmaceuticals Company GmbH (“Amneal”), an affiliate of Amneal Pharmaceuticals LLC, a leading generics manufacturer, today announced the execution of an exclusive development and license agreement with Iconovo AB, a developer of dry powder inhalers.  Under the agreement, Amneal will leverage Iconovo’s reservoir inhaler, ICOres, and dry powder formulation for a generic inhalation product to treat asthma and chronic obstructive pulmonary disease (COPD).  This collaboration will complement Amneal’s current pipeline of inhalation products in markets outside the United States. Amneal expects to manufacture these products in its Cashel, Ireland facility in the future. Additionally, Amneal continues to develop inhalation products for the U.S. markets through its internal R&D, with several products in advanced stages of development.    “Addressing today’s global health challenges requires innovative thinking and creative approaches. This collaboration with Iconovo, leveraging its unique technology platform, will enable us to bring quality, affordable medicines to markets outside the United States,” said Chirag Patel, chairman of the board of Amneal Pharmaceuticals Company GmbH. “It also further strengthens our commitment to invest in complex technologies and therapeutic categories that we believe will benefit human health.”    
About AmnealAmneal Pharmaceuticals Company GmbH is an affiliate of Amneal Pharmaceuticals LLC, a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods.  Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth.  The company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value.  Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international operations in Zug, Switzerland.  For more information, please visit  
EuropeHanumantha Rao Kamma T: +41 41 749 2906 
United States Laurene Isip T: +1.908.409.6819